GeoVax to Present at the Emerging Growth Conference on August 21, 2024
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Company to Discuss Recent Mpox Developments as Well as Milestones Related to the
BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine
公司将讨论最近的Mpox发展以及与BARDA项目NextGen奖项有关的里程碑
生物-疫苗公司将为其下一代COVID-19疫苗获得BARDA项目NextGen奖项的里程碑进行讨论
ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to present at the next Emerging Growth Conference being held August 21-22, 2024. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman and CEO, David Dodd, in real time.
2024年8月15日,美国佐治亚州亚特兰大(GLOBE NEWSWIRE)——生物技术公司GeoVax Labs,Inc.(纳斯达克:GOVX)正在开发针对癌症和传染性疾病的免疫治疗和疫苗,欣然宣布,它已经被邀请参加下一届Emerging Growth Conference,该会议将于2024年8月21-22日举行。这个在线互动活动将为现有股东和投资界提供与公司主席和首席执行官David Dodd实时互动的机会。
Mr. Dodd will be presenting at 4:10pm ET on Wednesday, August 21, 2024. Following his presentation, Mr. Dodd will open the floor for questions, time permitting. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and Mr. Dodd will do his best to get through as many of them as possible. Please register here to ensure you are able to attend the conference and receive any updates that are released. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, .
Dodd先生将于2024年8月21日星期三下午4:10 ET演讲。在他的演讲结束后,Dodd先生将开放问题环节,如果时间允许,请提前将您的问题提交到Questions@EmergingGrowth.com,或在活动期间提出您的问题,Dodd先生将尽力回答尽可能多的问题。请在此处注册以确保您能够参加会议并接收发布的任何更新。如果与会者无法在会议当天实时加入活动,则EmergingGrowth.com和Emerging Growth YouTube频道将提供存档网络广播。
About the Emerging Growth Conference
关于Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community. The conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts. All sessions are conducted through video webcasts and take place in the Eastern time zone.
Emerging Growth Conference是向投资界展示和传达公共公司新产品、服务以及其他重大公告的有效方式。会议的焦点和覆盖面包括增长领域的许多公司,这些公司拥有强大的管理团队、创新的产品和服务、明确的策略、执行力以及长期增长的总体潜力。其受众包括成千上万的个人和机构投资者,以及投资顾问和分析师。所有会议都通过视频网络广播进行,并在东部时间区域举行。
About GeoVax
关于GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: .
GeoVax Labs,Inc.是一家临床阶段的生物技术公司,为世界上最具威胁的传染病开发新型疫苗和固体肿瘤癌症的治疗方案。该公司的主要临床项目是GEO-CM04S1,这是一种下一代COVID-19疫苗,GeoVax最近获得了一个BARDA资助的合同,赞助一项10,000参与者的第20亿期临床试验,以评估GEO-CM04S1与经批准的COVID-19疫苗的疗效。此外,正在对GEO-CM04S1进行三个第2期临床试验评估,作为(1)免疫系统受损患者的主要疫苗,例如患血液肿瘤和其他当前授权的COVID-19疫苗不足的患者人群,(2)慢性淋巴细胞白血病(CLL)患者的诱导疫苗和(3)之前接种mRNA疫苗的健康患者更强、更持久的COVID-19增强剂。在肿瘤学中,主要临床项目正在多中心第1/2期临床试验中评估一种新型的肿瘤基因定向治疗Gedeptin,用于晚期头颈癌的治疗。GeoVax在支持其技术和产品的强大知识产权组合方面拥有强大的IP组合,全球拥有其技术和产品的权利。多个生命科学公司的领导团队在过去的几十年中推动了显着的价值创造。有关我们临床试验和其他更新的当前状态的更多信息,请访问我们的网站。
Company Contact: | Investor Relations Contact: | Media Contact: | ||
info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
678-384-7220 | 212-698-8696 | 202-779-0929 |
公司联系人: | 投资者关系联系人: | 媒体联系人: | ||
info@geovax.com | austin.murtagh@precisionaq.com | sr@roberts-communications.com | ||
678-384-7220 | 212-698-8696 | 202-779-0929 |